|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 323.20 SEK | +1.89% |
|
-2.30% | +3.99% |
| 08/05 | US FDA Extends Review Period for BioArctic's Co-developed Alzheimer's Therapy | MT |
| 08/05 | Futures point to negative opening for Stockholm Stock Exchange (update) | FW |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -8.97 | -0.56 | 15.71 | -12.49 | 46.39 | |||||
Return on Total Capital | -10.09 | -0.62 | 17.38 | -14.35 | 57.77 | |||||
Return On Equity % | -14.13 | -1.42 | 25.02 | -18.24 | 71.44 | |||||
Return on Common Equity | -14.13 | -1.42 | 25.02 | -18.24 | 71.44 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -114.58 | 67.6 | 85.45 | 89.51 | 97.04 | |||||
SG&A Margin | 379.34 | 64.8 | 40.79 | 57.84 | 9.75 | |||||
EBITDA Margin % | -523.12 | -0.77 | 44.71 | -82.06 | - | |||||
EBITA Margin % | -544.96 | -3.46 | 41.71 | -89.22 | 68.44 | |||||
EBIT Margin % | -544.96 | -3.46 | 41.71 | -89.22 | 68.44 | |||||
Income From Continuing Operations Margin % | -466.78 | -4.87 | 37.22 | -68.81 | 51.14 | |||||
Net Income Margin % | -466.78 | -4.87 | 37.22 | -68.81 | 51.14 | |||||
Net Avail. For Common Margin % | -466.78 | -4.87 | 37.22 | -68.81 | 51.14 | |||||
Normalized Net Income Margin | -342.19 | -3.04 | 28.05 | -46.03 | 39.25 | |||||
Levered Free Cash Flow Margin | -353.02 | -14.97 | 34.24 | -112.8 | 58.06 | |||||
Unlevered Free Cash Flow Margin | -350.98 | -14.81 | 34.27 | -112.8 | 58.12 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.03 | 0.26 | 0.6 | 0.22 | 1.08 | |||||
Fixed Assets Turnover | 0.7 | 6.65 | 18.56 | 4.03 | 22.26 | |||||
Receivables Turnover (Average Receivables) | - | - | - | 7.21 | 20.73 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 8.51 | 11.58 | 9.22 | 5.75 | 4.78 | |||||
Quick Ratio | 8.47 | 11.47 | 9.15 | 5.65 | 4.76 | |||||
Operating Cash Flow to Current Liabilities | -1.39 | -0.45 | 2.48 | -1.8 | 2.75 | |||||
Days Sales Outstanding (Average Receivables) | - | - | - | 50.79 | 17.6 | |||||
Average Days Payable Outstanding | 86.6 | 81.79 | 104.58 | 544.71 | 229.28 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 2.01 | 1.28 | 0.48 | 6.06 | 2.24 | |||||
Total Debt / Total Capital | 1.97 | 1.26 | 0.47 | 5.71 | 2.19 | |||||
LT Debt/Equity | 0.99 | 0.15 | 0.21 | 4.59 | 1.44 | |||||
Long-Term Debt / Total Capital | 0.97 | 0.15 | 0.2 | 4.33 | 1.41 | |||||
Total Liabilities / Total Assets | 12.15 | 8.4 | 11.76 | 19.5 | 23.62 | |||||
EBIT / Interest Expense | -166.89 | -14.2 | 783.41 | - | 675.34 | |||||
EBITDA / Interest Expense | -150.76 | 11.17 | 873.09 | - | 682.85 | |||||
(EBITDA - Capex) / Interest Expense | -155.99 | -11.63 | 850.4 | - | 677.79 | |||||
Total Debt / EBITDA | -0.13 | 1.61 | 0.02 | -0.27 | 0.03 | |||||
Net Debt / EBITDA | 6.59 | -127.34 | -3.86 | 3.67 | -1.55 | |||||
Total Debt / (EBITDA - Capex) | -0.12 | -1.54 | 0.02 | -0.24 | 0.03 | |||||
Net Debt / (EBITDA - Capex) | 6.37 | 122.36 | -3.97 | 3.23 | -1.56 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -60.64 | 794.02 | 168.49 | -58.22 | 676.8 | |||||
Gross Profit, 1 Yr. Growth % | -296.5 | -627.5 | 239.36 | -61.67 | 742.09 | |||||
EBITDA, 1 Yr. Growth % | 71.04 | -98.69 | -14.81T | -176.69 | - | |||||
EBITA, 1 Yr. Growth % | 69.9 | -94.32 | -3.34T | -189.36 | -695.88 | |||||
EBIT, 1 Yr. Growth % | 69.9 | -94.32 | -3.34T | -189.36 | -695.88 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 74.83 | -90.67 | -2.15T | -177.24 | -677.33 | |||||
Net Income, 1 Yr. Growth % | 74.83 | -90.67 | -2.15T | -177.24 | -677.33 | |||||
Normalized Net Income, 1 Yr. Growth % | 62.47 | -92.05 | -2.58T | -168.55 | -762.51 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 74.4 | -90.44 | -2.09T | -177.39 | -674.75 | |||||
Accounts Receivable, 1 Yr. Growth % | - | - | - | 31.83T | 70.86 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -15.5 | 4.49 | -11.73 | 210.42 | -14.11 | |||||
Total Assets, 1 Yr. Growth % | -14.53 | -4.39 | 38.19 | -6.27 | 131.65 | |||||
Tangible Book Value, 1 Yr. Growth % | -13.07 | -0.31 | 33.11 | -14.49 | 119.8 | |||||
Common Equity, 1 Yr. Growth % | -13.07 | -0.31 | 33.11 | -14.49 | 119.8 | |||||
Cash From Operations, 1 Yr. Growth % | 52.11 | -77.48 | -1.08T | -202.14 | -552.39 | |||||
Capital Expenditures, 1 Yr. Growth % | -64.84 | 190.61 | -41.61 | 257.85 | -61.54 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 29.04 | -62.3 | -712.39 | -237.63 | -503.92 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 29.42 | -62.46 | -719.27 | -237.5 | -504.36 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -69.88 | 87.58 | 389.93 | 5.91 | 80.15 | |||||
Gross Profit, 2 Yr. CAGR % | -62.63 | 221.95 | 323.1 | 21.87 | 79.66 | |||||
EBITDA, 2 Yr. CAGR % | 8.49 | -85 | 42.97 | 962.14 | - | |||||
EBITA, 2 Yr. CAGR % | 12.2 | -68.95 | 35.55 | 437.83 | 130.75 | |||||
EBIT, 2 Yr. CAGR % | 12.2 | -68.95 | 35.55 | 437.83 | 130.75 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 16.36 | -59.61 | 38.34 | 298 | 111.17 | |||||
Net Income, 2 Yr. CAGR % | 16.36 | -59.61 | 38.34 | 298 | 111.17 | |||||
Normalized Net Income, 2 Yr. CAGR % | 11.52 | -64.06 | 40.28 | 311.94 | 113.1 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 16.63 | -59.18 | 37.98 | 292.66 | 110.9 | |||||
Accounts Receivable, 2 Yr. CAGR % | 288.6 | - | -71.97 | - | 2.24T | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -4.67 | -6.04 | -3.96 | 65.53 | 63.28 | |||||
Total Assets, 2 Yr. CAGR % | -12.9 | -9.6 | 14.94 | 13.81 | 47.35 | |||||
Tangible Book Value, 2 Yr. CAGR % | -10.04 | -6.91 | 15.2 | 6.69 | 37.1 | |||||
Common Equity, 2 Yr. CAGR % | -10.04 | -6.91 | 15.2 | 6.69 | 37.1 | |||||
Cash From Operations, 2 Yr. CAGR % | -34.48 | -41.47 | 48.49 | 216.21 | 114.96 | |||||
Capital Expenditures, 2 Yr. CAGR % | 15.96 | 1.09 | 30.27 | 44.56 | 17.31 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -45.78 | -30.07 | 52.19 | 190.32 | 134.58 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -46 | -30.12 | 52.7 | 191.8 | 134.59 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -67.12 | -6.75 | 111.4 | 115.65 | 105.78 | |||||
Gross Profit, 3 Yr. CAGR % | -62.92 | -9.68 | 227.65 | 98.61 | 132.12 | |||||
EBITDA, 3 Yr. CAGR % | -34.96 | -75.08 | 51.95 | 16.17 | - | |||||
EBITA, 3 Yr. CAGR % | -33.97 | -58.5 | 46.15 | 17.97 | 456.52 | |||||
EBIT, 3 Yr. CAGR % | -33.97 | -58.5 | 46.15 | 17.97 | 456.52 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -32.04 | -49.82 | 49.57 | 13.92 | 350.54 | |||||
Net Income, 3 Yr. CAGR % | -32.04 | -49.82 | 49.57 | 13.92 | 350.54 | |||||
Normalized Net Income, 3 Yr. CAGR % | -34.04 | -53.76 | 47.32 | 10.49 | 382.64 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -32.02 | -49.34 | 49.19 | 13.79 | 345.83 | |||||
Accounts Receivable, 3 Yr. CAGR % | - | - | - | 192.7 | - | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 53.73 | -1.71 | -7.98 | 42 | 33.01 | |||||
Total Assets, 3 Yr. CAGR % | -13.62 | -10.15 | 4.14 | 7.39 | 44.23 | |||||
Tangible Book Value, 3 Yr. CAGR % | -8.15 | -6.91 | 4.88 | 4.3 | 35.75 | |||||
Common Equity, 3 Yr. CAGR % | -8.15 | -6.91 | 4.88 | 4.3 | 35.75 | |||||
Cash From Operations, 3 Yr. CAGR % | -11.12 | -54.1 | 49.69 | 31.08 | 256.3 | |||||
Capital Expenditures, 3 Yr. CAGR % | 1.02 | 57.51 | -15.81 | 82.44 | -7.03 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -32.92 | -51.88 | 44.29 | 47.17 | 223 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -32.98 | -52.08 | 44.76 | 47.45 | 224.22 | |||||
Dividend Per Share, 3 Yr. CAGR % | - | - | - | - | - | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -24.64 | 7.91 | -3.13 | -1.88 | 98.29 | |||||
Gross Profit, 5 Yr. CAGR % | -22.53 | 10.73 | -1.82 | 1.82 | 164.57 | |||||
EBITDA, 5 Yr. CAGR % | 15.88 | -41.61 | -10.81 | 13.11 | - | |||||
EBITA, 5 Yr. CAGR % | 17.41 | -19.87 | -11.96 | 15.63 | 75.44 | |||||
EBIT, 5 Yr. CAGR % | 17.41 | -19.87 | -11.96 | 15.63 | 75.44 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 15.78 | -5.91 | -9.69 | 14.89 | 71.7 | |||||
Net Income, 5 Yr. CAGR % | 15.78 | -5.91 | -9.69 | 14.89 | 71.7 | |||||
Normalized Net Income, 5 Yr. CAGR % | 13.64 | -10.14 | -10.8 | 10.9 | 70.76 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 8.3 | -10.21 | -9.77 | 14.92 | 71.35 | |||||
Accounts Receivable, 5 Yr. CAGR % | 34.96 | - | - | 227.84 | - | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 43 | 37.82 | 27.36 | 21.08 | 15.75 | |||||
Total Assets, 5 Yr. CAGR % | 4.86 | -5.53 | -3.17 | -1.24 | 19.65 | |||||
Tangible Book Value, 5 Yr. CAGR % | 66.98 | 4.33 | 0.56 | -1.69 | 16.74 | |||||
Common Equity, 5 Yr. CAGR % | 66.98 | 4.33 | 0.56 | -1.69 | 16.74 | |||||
Cash From Operations, 5 Yr. CAGR % | -26.95 | -25.22 | 9.13 | -0.67 | 73 | |||||
Capital Expenditures, 5 Yr. CAGR % | 8.13 | 29.89 | 11.83 | 52.19 | -3.86 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -32.69 | -24.95 | -6.81 | -1.19 | 75.25 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -32.77 | -25.06 | -6.74 | -1.23 | 75.6 |
- Stock Market
- Equities
- BIOA B Stock
- Financials BioArctic AB
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















